荟萃分析:COVID-19后功能性消化不良与肠易激综合征
该荟萃分析检索MEDLINE、Scopus和Embase至2022年12月17日,纳入报告COVID-19幸存者及对照者按罗马标准诊断的功能性消化不良(FD)和/或肠易激综合征(IBS)发生率的研究。COVID-19后FD报告率为4%(95%CI:3%-5%,I2=0%),IBS为12%(95%CI:8%-16%,I2=95.6%,Egger检验p=0.002)。COVID-19幸存者较对照者存在IBS发生风险,FD尚无确定性数据。
要点
- COVID-19后FD报告率为4%(95%CI:3%-5%,I2=0%),FD的汇总OR为8.07(95%CI:0.84-77.87,p=0.071,I2=67.9%),未达统计学显著。
- COVID-19后IBS报告率为12%(95%CI:8%-16%,I2=95.6%,Egger检验p=0.002)。
- IBS的汇总OR为6.27(95%CI:0.88-44.76,p=0.067,I2=81.4%);仅纳入前瞻性COVID-19队列研究时,汇总OR为12.92(95%CI:3.58-46.60,p<0.001,I2=0%)。
核心结论
- COVID-19幸存者较对照者存在IBS发生风险,FD尚无确定性数据。
研究设计与样本
- 荟萃分析,检索MEDLINE、Scopus和Embase至2022年12月17日,纳入报告COVID-19幸存者及对照者按罗马标准诊断的FD和/或IBS发生率的研究。
- FD分析纳入4项研究共1199例COVID-19患者;IBS分析纳入10项研究共2763例COVID-19患者。
主要发现
- COVID-19后FD由72例患者报告(4%,95%CI:3%-5%,I2=0%)。
- COVID-19后IBS由195例患者报告(12%,95%CI:8%-16%,I2=95.6%,Egger检验p=0.002)。
- COVID-19患者较对照者FD发生的汇总OR为8.07(95%CI:0.84-77.87,p=0.071,I2=67.9%,3项研究)。
- COVID-19患者较对照者IBS发生的汇总OR为6.27(95%CI:0.88-44.76,p=0.067,I2=81.4%,4项研究);仅纳入前瞻性COVID-19队列研究(3项)时,汇总OR为12.92(95%CI:3.58-46.60,p<0.001,I2=0%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- FD的汇总OR 95%CI宽(0.84-77.87)且I2=67.9%。
- IBS报告率异质性I2=95.6%,Egger检验p=0.002提示发表偏倚。
- IBS的汇总OR 95%CI宽(0.88-44.76)且I2=81.4%。
- FD尚无确定性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The burden of post-COVID-19 functional dyspepsia (FD) and irritable bowel syndrome (IBS) remains unclear. The aim of this meta-analysis was to estimate the rate of post-COVID-19 FD and IBS. METHODS: MEDLINE, Scopus and Embase were searched through 17 December 2022. Studies reporting the incidence of FD and/or IBS in COVID-19 survivors and controls (without COVID-19), when available, according to the Rome criteria, were included. Estimated incidence with 95% confidence intervals (CI) was pooled. The odds ratio (OR) with 95% confidence intervals (CI) was pooled; heterogeneity was expressed as I2 . RESULTS: Ten studies met the inclusion criteria and were included in the analysis. Overall, four studies including 1199 COVID-19 patients were considered for FD. Post-COVID-19 FD was reported by 72 patients (4%, 95% CI: 3%-5% and I2 0%). The pooled OR for FD development (three studies) in post-COVID-19 patients compared to controls was 8.07 (95% CI: 0.84-77.87, p = 0.071 and I2 = 67.9%). Overall, 10 studies including 2763 COVID-19 patients were considered for IBS. Post-COVID-19 IBS was reported by 195 patients (12%, 95% CI: 8%-16%, I2 95.6% and Egger's p = 0.002 test). The pooled OR for IBS development (four studies) in COVID-19 patients compared to controls was 6.27 (95% CI: 0.88-44.76, p = 0.067 and I2 = 81.4%); considering only studies with a prospective COVID-19 cohort (three studies), the pooled OR was 12.92 (95% CI: 3.58-46.60, p < 0.001 and I2 = 0%). CONCLUSIONS: COVID-19 survivors were found to be at risk for IBS development compared to controls. No definitive data are available for FD.
引用
- Marasco G, Maida M, Cremon C, et al. Meta-analysis: Post-COVID-19 functional dyspepsia and irritable bowel syndrome. Aliment Pharmacol Ther. 2023. PMID: 37038318. doi:10.1111/apt.17513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。